GlassScriptPhysician profile
Tyler C Goff
NPI 1881115665
$7,440.50
in general payments reported to CMS, 2019-2025
22 companies · $1,121 in 2025
The $1,121 reported for 2025 was more than what 80% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $239 · 2021: $205 · 2022: $854 · 2023: $1,925 · 2024: $3,097 · 2025: $1,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,394 · Travel and Lodging: $1,749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,393.88 |
| Travel and Lodging | $1,748.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $2,180.81 | 2022-2024 | |
| Alcon Vision LLC | $1,425.63 | 2022-2025 | Clareon, Rocklatan, Clareon Panoptix Pro |
| Glaukos Corporation | $728.83 | 2021-2025 | Kxl System (Not Refurbished), Kxl1b-Ce-Marked Kxlsystem |
| Johnson & Johnson Surgical Vision, INC. | $523.80 | 2021-2025 | Catalys System, Tecnis Iol, Tecnis Iol |
| Mallinckrodt Hospital Products INC. | $440.47 | 2022-2025 | Acthar |
| Rxsight INC | $272.35 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Tarsus Pharmaceuticals, INC. | $242.90 | 2024-2025 | Xdemvy |
| Allergan, INC. | $239.31 | 2019 | |
| Oyster Point Pharma, INC. | $234.86 | 2022-2025 | Tyrvaya, Ryzumvi |
| Sight Sciences, INC. | $213.19 | 2024-2025 | Omni Surgical System, Sion Surgical Instrument |
| Bausch & Lomb Americas INC. | $204.59 | 2022-2024 | Miebo, Lotemax Sm, Envista Mx60 Iol |
| Sun Pharmaceutical Industries INC. | $200.51 | 2022-2023 | Cequa |
| Abbvie INC. | $129.45 | 2022-2025 | |
| Dompe US, INC. | $110.79 | 2023-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $79.56 | 2022-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $64.65 | 2023-2024 | Dextenza |
| Harrow Eye, LLC | $47.95 | 2025 | Vevye |
| Ani Pharmaceuticals, INC. | $31.21 | 2025 | Purified Cortrophin Gel |
| Amgen INC. | $19.89 | 2024 | Tepezza |
| Rayner Intraocular Lenses Limited | $18.46 | 2022 | |
| New World Medical,INC. | $16.59 | 2025 | Via360, Kahook Dual Blade, Ahmed Glaucoma Valve |
| Coopervision INC. | $14.70 | 2025 | Biofinity Contact Lens |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Goff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.